Updated Research Note
MedPal AI plc has released an updated research note from Optimo Research and an investor interview with CEO Jason Drummond, highlighting significant progress since its August 2025 IPO. The company has processed over 200,000 prescription orders, driven by AI-driven diagnostics, clinician access, and robotic dispensing. This news follows a partnership with Epassi UK Limited, granting access to over 11 million employees.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce the release of an updated research note by Optimo Research, alongside a new investor interview with CEO Jason Drummond.
On Thursday 2 April, Optimo Research Ltd updated its coverage of MedPal AI, covering the significant progress made by the company since its IPO in August 2025.
The research can be downloaded on the Optimo Research website here:
In addition, in a new investor interview CEO Jason Drummond has shared how a combination of AI-driven diagnostics, clinician access, and robotic dispensing has enabled rapid growth, with over 200,000 prescription orders processed since launch. The interview can be accessed on the ADVFN website here:
X: @MedPalPlc
LinkedIn: MedPal AI plc
About Reach announcements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.